ProteoSys AG innovation in functional proteomics
home contact technology fee for
company publications cooperation
ProteoSys AG
Carl-Zeiss-Str. 51
55129 Mainz | Germany
tel: +49 6131 501920
fax: +49 6131 5019211
Who we are
ProteoSys is a commercial research institution (SME) with a systems biology approach. We have leading expertise in the discovery and validation of protein biomarkers and biomarker signatures for diagnostic use, control of  therapies and therapy development.

What sets us apart
ProteoSys provides high content information using a proprietary core technology: ProteoTope™. It gives us the unique advantage of reducing the complexity of protein patterns to the few significant differential protein biomarkers. [find_out_more]

ProteoSys has established a highly efficient process of integration of cell biology and the synchronisation of protein pattern changes. This is key for the understanding of biology and the prediction of treatment outcomes or disease progression. [find_out_more]

What we do
With this expert background, ProteoSys is a key contributor to research projects in the fields of CNS therapies, diagnostics and toxicology. We also provide contract services (fee-for-service) for industry and academia.

What we achieved
Annexin ANXA3 is a new diagnostic marker for body fluid and tissue for the early detection of prostate cancer and the prognosis of its progression. [find_out_more]

PSY-130/131 is a product from ProteoSys' drug reprofiling programme. It has been developed for the treatment of Alzheimer’s disease and is currently in clinical phase II. [find_out_more]

NRG 101 is currently in late preclinical development as a disease-modifying treatment for Parkinson's disease. [find_out_more]

AXLR8-2 Workshop "Roadmap to Innovative Toxicity testing", 23.-25.5.2011 Berlin-Dahlem
Invited talk: A. Schrattenholz

Kick-Off Meeting of the SEURAT-1 research initiative, 1-3 March 2011, Cascais, Portugal

PharmaForum 2010 Mainz - 3 Nov 2010,
Invited speaker: A. Schrattenholz
Protein Biomarkers and Systems Biology
[download PDF]

Mind-NRG secures Series A financing from Index Ventures Company developing disease modifying compounds for CNS disorders
[Press release, 27 Oct 2010]

Verleihung des 29. Tierschutz-Forschungspreises - 15 Dec 2010, Invited speaker: A. Schrattenholz
[Press release]

Rösler TW et al. (2011):
Biodistribution and brain permeability of the extracellular domain of neuregulin-1-ß1
Neuropharmacology. 2011 Aug 31. [Epub ahead of print] [pubmed]

Carlson T et al. (2011):
Systemic administration of neuregulin-1ß1 protects dopaminergic neurons in a mouse model of Parkinson's disease
J Neurochem. 2011 Jun;117(6):1066-74. doi: 10.1111/j.1471-4159.2011.07284.x. Epub 2011 May 13 [pubmed]

Schrattenholz A et al. (2010):
Systems Biology Approaches and Tools for Analysis of Interactomes and Multi-Target Drugs
Methods Mol Biol 662: 29. [pubmed]

Schrattenholz A et al. (2010):
Systems Biology Approaches and Tools for Analysis of Interactomes and Multi-Target Drugs
Methods Mol Biol 662: 29. [pubmed]

Groebe K et al. (2010):
Protein biomarkers for in vitro testing of embryotoxicity
J Proteome Res 9: 5727. [pubmed]

Schrattenholz A et al. (2010)
Synchronization of posttranslational modifications during aging
Ann NY Acad Sci 1197: 118. [pubmed]

Groebe K et al. (2010)
Unexpected common mechanistic pathways for embryotoxicity of warfarin and lovastatin
Reprod Toxicol 30: 121. [pubmed]

Kuegler et al. (2010)
Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing
ALTEX 27: 17. [pubmed]

Groebe K et al. (2010)
Age-dependent posttranslational modifications of voltage-dependent anion channel 1 and the role of the mitochondrial transition pore
Exp Gerontol 45: 632. [pubmed]

Shakib K et al. (2010):
Stem Cells in Head and Neck Squamous Cell Carcinoma
Br J Oral Maxillofac Surg: in press. [pubmed]